MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

0
Player Avatar mjguerrera (< 20) Submitted: 1/19/2011 7:50:24 PM : Underperform Start Price: $5.07 MNKD Score: +69.51

This stock is going to $0.

Report this Post Reply

Featured Broker Partners


Advertisement